Holen Sie sich die Stockscreener-App
1.23
0.82%
0.01
Vorhandelsmarkt:
1.24
0.01
+0.81%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.22
Offen:
$1.23
24-Stunden-Volumen:
1.74M
Relative Volume:
0.91
Marktkapitalisierung:
$232.03M
Einnahmen:
$154.90M
Nettoeinkommen (Verlust:
$-20.20M
KGV:
-10.21
EPS:
-0.1205
Netto-Cashflow:
$-27.91M
1W Leistung:
+1.65%
1M Leistung:
+53.90%
6M Leistung:
+10.81%
1J Leistung:
-42.25%
1-Tages-Spanne:
$1.19
$1.24
1-Wochen-Bereich:
$1.16
$1.30
52-Wochen-Spanne:
$0.7362
$2.61
Heron Therapeutics Inc Stock (HRTX) Company Profile
Firmenname
Heron Therapeutics Inc
Sektor
Branche
Telefon
(858) 251-4400
Adresse
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.23 | 232.03M | 154.90M | -20.20M | -27.91M | -0.1205 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-04-23 | Eingeleitet | CapitalOne | Overweight |
| 2024-03-13 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Buy |
| 2020-02-20 | Bestätigt | Needham | Buy |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-04-05 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2018-03-01 | Bestätigt | Needham | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Outperform |
| 2017-09-27 | Eingeleitet | Northland Capital | Outperform |
| 2017-02-27 | Eingeleitet | Needham | Buy |
| 2016-10-26 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-06 | Fortgesetzt | Lake Street | Buy |
| 2016-05-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-10 | Eingeleitet | Lake Street | Buy |
| 2015-09-23 | Bestätigt | Leerink Partners | Outperform |
| 2015-09-02 | Eingeleitet | BofA/Merrill | Buy |
| 2015-08-03 | Bestätigt | Brean Capital | Buy |
| 2015-06-30 | Bestätigt | JMP Securities | Mkt Outperform |
| 2015-06-19 | Bestätigt | Leerink Partners | Outperform |
| 2014-08-07 | Eingeleitet | Noble Financial | Buy |
Alle ansehen
Heron Therapeutics Inc Aktie (HRTX) Neueste Nachrichten
Heron Therapeutics (HRTX) COO gains 11,770 shares through RSU conversion - Stock Titan
Heron EVP exercises RSUs into 23,464 common shares | HRTX Insider Trading - Stock Titan
[Form 4] HERON THERAPEUTICS, INC. /DE/ Insider Trading Activity - Stock Titan
Heron Therapeutics (NASDAQ: HRTX) CEO converts 84,810 RSUs to shares - Stock Titan
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
[ARS] HERON THERAPEUTICS, INC. /DE/ SEC Filing - Stock Titan
Heron Therapeutics (NASDAQ: HRTX) seeks approval for major new equity pools - Stock Titan
Heron Therapeutics (NASDAQ:HRTX) Downgraded by Zacks Research to "Strong Sell" - MarketBeat
Heron Therapeutics (HRTX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026 - Sahm
Heron sets May 11 webcast for Q1 results and business updates - Stock Titan
Heron Therapeutics outlines $173M–$183M 2026 sales targets amid acute care momentum and expanded commercial investment - MSN
Research Analysts Set Expectations for HRTX Q1 Earnings - MarketBeat
HRTX Edges Higher As Insider Ownership Change Draws Attention - StocksToTrade
Heron Therapeutics files $125M mixed securities shelf - MSN
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
HC Wainwright Cuts Earnings Estimates for Heron Therapeutics - MarketBeat
Heron CEO exercises 13,797 RSUs into shares | HRTX Insider Trading - Stock Titan
Heron Therapeutics (NASDAQ: HRTX) seeks shareholder approval to add 26.56M shares across incentive plans - Stock Titan
Heron Therapeutics (HRTX) Stock: Final Thoughts (-1.75%) 2026-04-16Low Volatility Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Heron Therapeutics, Inc. (HRTX) Stock Analysis: A Promising 352.95% Potential Upside Worth Exploring - DirectorsTalk Interviews
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo
EBITDA per share of Heron Therapeutics Inc – LSE:0J4V - TradingView — Track All Markets
Total debt per share of Heron Therapeutics Inc – LSE:0J4V - TradingView — Track All Markets
Pullback Watch: Can Heron Therapeutics Inc expand into new markets2026 Sector Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
What scenarios affect Heron Therapeutics (HRTX) Stock price | Price at $0.81, Up 3.09%Buy Opportunities - Cổng thông tin điện tử tỉnh Tây Ninh
Heron Therapeutics (HRTX) CEO exercises 62,500 RSUs into common stock - Stock Titan
Earnings Miss: How does Heron Therapeutics Inc compare to its peersQuarterly Trade Summary & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Heron Therapeutics Executive Employment Agreements: Key Terms, Termination, and Restrictive Covenants Explained - Minichart
Heron Therapeutics Strengthens Executive Contracts Amid Strategic Focus - TipRanks
Heron Therapeutics (NASDAQ: HRTX) revises executive severance and CIC - Stock Titan
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of "Hold" by Analysts - marketbeat.com
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of “Hold” by Analysts - Defense World
HRTX Stock Analysis: Heron Therapeutics Inc. Biotech Stock at $0.8 After Minor Daily Dip - Cổng thông tin điện tử tỉnh Lào Cai
HRTX Stock Price, Quote & Chart | HERON THERAPEUTICS INC (NASDAQ:HRTX) - ChartMill
Q1 Earnings Forecast for HRTX Issued By Northland Securities - MarketBeat
Moving Averages: How does Heron Therapeutics Inc compare to its peersWeekly Risk Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
Wall Street Recap: How does Heron Therapeutics Inc compare to its peersTrade Entry Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Vanguard realigns holdings; Heron Therapeutics (HRTX) ownership shown as 0 - Stock Titan
What is Northland Securities' Estimate for HRTX Q3 Earnings? - MarketBeat
If You Invested $1,000 in Heron Therapeutics Inc (HRTX) - Stock Titan
Heron Therapeutics, Inc. (HRTX) Investor Outlook: A 415% Upside Potential In Biotechnology - DirectorsTalk Interviews
Market Trends: Is Heron Therapeutics Inc stock technically oversold2026 Key Highlights & Daily Momentum Trading Reports - baoquankhu1.vn
Clearline Capital LP Increases Holdings in Heron Therapeutics, Inc. $HRTX - MarketBeat
Baker BROS. Advisors LP Purchases New Position in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron Therapeutics, Inc. (HRTX) Stock Analysis: Exploring a Promising 346% Potential Upside - DirectorsTalk Interviews
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
HRTX SEC FilingsHeron Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Citigroup Inc. Increases Stock Position in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron Therapeutics Signals Profitable Growth After Strong Quarter - TipRanks
Finanzdaten der Heron Therapeutics Inc-Aktie (HRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):